+12%

est. 2Y upside i

Healthcare

Discovering the true signals of disease to power life-changing drugs.

Rank

#1823

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Given significant data gaps, the equity upside is highly uncertain.

Last updated: July 3, 2026

Bull (10%)+140%

Strong drug target discovery leads to a partnership exit at $200M; common stock gains 140% net of 20% dilution.

Base (45%)+83%

Steady progress leads to a $60M exit; common stock returns 83% after dilution, reflecting moderate commercialization.

Bear (45%)-89%

Failure to secure funding or competitive pressure drives exit to $10M; common stock loses 89% as preference overhang dominates.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

2240%

1x non-participating preference on $6.72M, representing 22.4% of assumed $30M valuation.

Dilution Risk

high

Likely raise within 24 months due to low cash and no recent funding; assumes 20% dilution.

Secondary Liquidity

none

No secondary market data available; liquidity expected only at exit.

View all 2 open roles at Sequence Bio →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Sequence Bio's data — designed to show you've done your homework.

  • 1

    “How will Sequence Bio secure a Series B/C given 5 years since last round?”

  • 2

    “What is the path to revenue and profitability?”

  • 3

    “What is the current share count and option pool? Is there a secondary market for employee shares?”

Community

Valuation Sentiment

Our model estimates +12% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.